Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade

Valerie Lee(Sidney Kimmel Cancer Center), Luis A. Díaz(Memorial Sloan Kettering Cancer Center)
The Oncologist
July 13, 2016
10.1634/theoncologist.2016-0046
Cited by 276

Related Papers

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Immunotherapy in colorectal cancer: rationale, challenges and potential
|Nature Reviews Gastroenterology & Hepatology|2019|2k
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
|The Lancet Oncology|2022|872
Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin
|UNC Libraries|2020|0